MedPath

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1
Suspended
Conditions
Pancreatic Cancer
Registration Number
NCT00209677
Lead Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Brief Summary

To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and survival period. By performing a phase I/II study of this combination in patients with inoperable or with postoperative pancreatic cancer.

Detailed Description

A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on patients with histological stage IV Pancreatic cancer given gemcitabine plus S-1. The usefulness of this regimens as 1st line therapy for pancreatic cancer was evaluated by the disease-free survival(DFS), median survival time (MST), incidence and severity of adverse event.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
40
Inclusion Criteria
  1. Histological diagnosis of pancreatic adenocarcinoma.
  2. Measurable or assessable lesions(Except for Phase I).
  3. Age: 20 ~ 75 years.
  4. Kar-nofsky Performance Status (KPS) > 70.
  5. No prior chemotherapy
  6. No history of treatment with gemcitabine or S-1.
  7. No history of radiotherapy to the abdomen.
  8. Oral intake of S-1 is possible.
  9. Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC 3,500/mm3 and Neutrophil 2,000/mm3. Hb 9.0 g/dl. Platelet count 100,000/mm3. GOT and GPT 2.5 times the upper limit of normal (excluding liver metastasis). T-Bil 2.0 mg/dl. Creatinine within the upper limit of normal). Normal ECG (not considering clinically unimportant arrhythmias and ischemic changes).
  10. Predicted survival for >3 months.
  11. Able to give written informed consent.
Read More
Exclusion Criteria
  1. Severe pleural effusion or ascites.
  2. Metastasis to the central nervous system (CNS).
  3. Active gastrointestinal bleeding.
  4. Active infection.
  5. Liver cirrhosis
  6. Uncontrolled ischemic heart disease.
  7. Serious complications (such as intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure, or hepatic failure).
  8. Active multiple cancer.
  9. Severe mental disorder.
  10. Pregnancy, possible pregnancy, or breast-feeding.
  11. Flucytosine treatment
  12. Judged to be ineligible for this protocol by the attending physician.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting.
Determine the clinical response rate with Recommended dose in Phase II setting.
Secondary Outcome Measures
NameTimeMethod
Determine the clinical response rate of patients in Phase I setting.
Determine the MST(Median Survival Time) and DFS(Disease Free Survival) in Phase II setting.

Trial Locations

Locations (1)

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine)

🇯🇵

Sapporo, Hokkaido, Japan

Hokkaido University Hospital (Hokkaido University Graduate School of Medicine)
🇯🇵Sapporo, Hokkaido, Japan
© Copyright 2025. All Rights Reserved by MedPath